XML 34 R23.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Income Taxes | 12 Months Ended
--- | ---
Jan. 31, 2025
Income Tax Disclosure [Abstract] |
Income Taxes | Note 13. Income Taxes The components of income before income taxes were as follows (in thousands):
|  | Year Ended January 31, |
|  | 2025 |  |  | 2024 |  |  | 2023 |
United States |  | $ | 13,890 |  |  | $ | 14,174 |  |  | $ | (7,103 | )
Foreign |  |  | 71,270 |  |  |  | 48,412 |  |  |  | 41,510 |
Total |  | $ | 85,160 |  |  | $ | 62,586 |  |  | $ | 34,407 |
The components of (benefit from) provision for income taxes were as follows (in thousands):
|  | Year Ended January 31, |
|  | 2025 |  |  | 2024 |  |  | 2023 |
Current: |  |  |  |  |  |  |  |  |
State |  | $ | 1,196 |  |  | $ | 1,887 |  |  | $ | 1,431 |
Foreign |  |  | 10,568 |  |  |  | 6,959 |  |  |  | 4,546 |
Total |  |  | 11,764 |  |  |  | 8,846 |  |  |  | 5,977 |
Deferred: |  |  |  |  |  |  |  |  |
Federal |  |  | (154,032 | ) |  |  | (91 | ) |  |  | 58 |
State |  |  | (23,614 | ) |  |  | 59 |  |  |  | 65 |
Foreign |  |  | 6,421 |  |  |  | (75,260 | ) |  |  | 1,524 |
Total |  |  | (171,225 | ) |  |  | (75,292 | ) |  |  | 1,647 |
(Benefit from) provision for income taxes |  | $ | (159,461 | ) |  | $ | (66,446 | ) |  | $ | 7,624 |
The following is a reconciliation of the difference between the effective income tax rate and the federal statutory rate of 21% (in thousands):
|  | Year Ended January 31, |
|  | 2025 |  |  | 2024 |  |  | 2023 |
Tax at statutory federal rate |  | $ | 17,884 |  |  | $ | 13,139 |  |  | $ | 7,225 |
State taxes, net of federal benefit |  |  | 2,782 |  |  |  | 3,792 |  |  |  | (1,794 | )
U.S. tax on foreign earnings |  |  | 17,389 |  |  |  | 14,569 |  |  |  | 14,357 |
Foreign rate difference |  |  | 2,022 |  |  |  | 819 |  |  |  | (53 | )
Nondeductible expenses |  |  | 828 |  |  |  | 701 |  |  |  | 893 |
Induced conversion expense |  |  | 2,129 |  |  |  | — |  |  |  | — |
Research and development credit |  |  | (7,880 | ) |  |  | (7,916 | ) |  |  | (6,870 | )
Change in reserve for unrecognized tax benefits |  |  | 7,880 |  |  |  | 7,916 |  |  |  | 6,870 |
Stock-based compensation |  |  | 1,032 |  |  |  | 3,555 |  |  |  | (7,069 | )
Change in valuation allowance, including the effect of tax rate change |  |  | (203,542 | ) |  |  | (102,573 | ) |  |  | (5,995 | )
Other |  |  | 15 |  |  |  | (448 | ) |  |  | 60 |
Total (benefit from) provision for income taxes |  | $ | (159,461 | ) |  | $ | (66,446 | ) |  | $ | 7,624 |
The significant components of our deferred tax assets and liabilities were as follows (in thousands):
|  | January 31, |
|  | 2025 |  |  | 2024 |
Deferred tax assets: |  |  |  |  |  |
Net operating loss carryover |  | $ | 149,519 |  |  | $ | 194,008 |
Stock-based compensation |  |  | 10,365 |  |  |  | 9,426 |
Capitalized research and development |  |  | 93,398 |  |  |  | 76,361 |
Depreciation and amortization |  |  | 11,218 |  |  |  | 11,428 |
Operating lease liabilities |  |  | 20,582 |  |  |  | 28,050 |
Other |  |  | 10,012 |  |  |  | 11,692 |
Total deferred tax assets |  |  | 295,094 |  |  |  | 330,965 |
Valuation allowance |  |  | (28,526 | ) |  |  | (230,686 | )
Total deferred tax assets, net of valuation allowance |  |  | 266,568 |  |  |  | 100,279 |
Deferred tax liabilities: |  |  |  |  |  |
Operating lease right-of-use assets, net |  |  | (15,307 | ) |  |  | (21,291 | )
Deferred commissions |  |  | (3,502 | ) |  |  | (2,836 | )
Goodwill with indefinite life amortization |  |  | (1,932 | ) |  |  | (1,505 | )
Other |  |  | (57 | ) |  |  | — |
Total deferred tax liabilities |  |  | (20,798 | ) |  |  | (25,632 | )
Net deferred tax assets |  | $ | 245,770 |  |  | $ | 74,647 |
We assess the realizability of deferred tax assets by considering whether it is more likely than not that some portion or all the deferred tax assets will not be realized. As a result, we continue to maintain a valuation allowance against our California deferred tax assets to the extent they are not offset by liabilities from uncertain tax positions. In the fourth quarter of fiscal year 2025, we concluded that it is more likely than not that our U.S. federal and state deferred tax assets, with the exception of California, are realizable. We released $201.2 million of our valuation allowance associated with the U.S. federal and state deferred tax assets. These U.S. federal and state deferred tax assets were created primarily as a result of net operating loss carryforwards from historical business operations. A significant improvement in our profitability over the last three years coupled with anticipated future earnings provided positive evidence to support the conclusion that sufficient taxable income will be generated in the future and a valuation allowance is no longer necessary. As of January 31, 2025, we maintained our valuation allowance associated with the California state deferred tax assets. During the years ended January 31, 2025 and 2024, the valuation allowance decreased by $202.2 million and $101.2 million, respectively. Provisions enacted in the 2017 Tax Cuts and Jobs Act related to the capitalization for tax purposes of research and experimental (R&E) expenditures became effective for tax years beginning after December 31, 2021. Beginning in the year ended January 31, 2023, we began capitalizing and amortizing R&E expenditures over five years for domestic research and 15 years for international research rather than expensing these costs as incurred. As a result, we recorded a net deferred tax asset of $90.2 million and $68.0 million, respectively, related to the capitalization requirement during the years ended January 31, 2025 and 2024. As of January 31, 2025, we had federal, state and foreign net operating loss carryforwards of $233.7 million, $487.3 million and $268.5 million, respectively, available to offset future taxable income. The federal net operating loss carryforwards generated prior to fiscal year 2019 will expire at various dates beginning in 2037, if not utilized. We have federal net operating loss carryforwards of $125.3 million, which can be carried forward indefinitely. The state net operating loss carryforwards will expire at various dates beginning in 2027, if not utilized. The foreign net operating loss carryforwards do not expire. In addition, as of January 31, 2025, we had federal and state research and development tax credit carryforwards of $69.4 million and $65.6 million, respectively. The federal research and development tax credit carryforwards will expire beginning in 2026, if not utilized. The state research and development tax credit carryforwards do not expire. Utilization of the federal and state net operating loss may be subject to substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization. We completed a Section 382 ownership change analysis through fiscal year 2025 tax periods, which concluded that our net operating losses are not permanently limited. Subsequent ownership changes may further affect the limitation in future years but we do not expect that the annual limitations will significantly impact our ability to utilize net operating loss or tax credit carryforward. We evaluate tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. We believe that we have provided adequate reserves for our income tax uncertainties in all open tax years. A reconciliation of the gross unrecognized tax benefits is as follows (in thousands):
|  | Year Ended January 31, |
|  | 2025 |  |  | 2024 |  |  | 2023 |
Unrecognized tax benefits—beginning of period |  | $ | 118,981 |  |  | $ | 103,636 |  |  | $ | 90,678 |
Reductions for tax positions related to prior year |  |  | (49 | ) |  |  | — |  |  |  | — |
Additions for tax positions related to prior year |  |  | — |  |  |  | 1,733 |  |  |  | 209 |
Additions for tax positions related to current year |  |  | 13,642 |  |  |  | 13,612 |  |  |  | 12,749 |
Unrecognized tax benefits—end of period |  | $ | 132,574 |  |  | $ | 118,981 |  |  | $ | 103,636 |
It is reasonably possible that within the next 12 months our unrecognized tax benefits related to these matters may decrease by up to approximately $70.0 million due to refinement of certain tax return positions. As of January 31, 2025, the balance of unrecognized tax benefits was $132.6 million of which $69.1 million, if recognized, would affect the effective tax rate and $63.5 million would result in adjustment to deferred tax assets with corresponding adjustments to the valuation allowance. The gross unrecognized tax benefits, if recognized, would not materially affect the effective tax rate as of January 31, 2024 and 2023. Our policy is to classify interest and penalties associated with uncertain tax positions, if any, as a component of our income tax provision. Interest and penalties were not significant during the years ended January 31, 2025, 2024 and 2023. We file tax returns in the U.S. for federal, California, and other states. All tax years remain open to examination for both federal and state purposes as a result of our net operating loss and credit carryforwards. We file tax returns in the U.K. and other foreign jurisdictions in which we operate. Tax years 2021 onwards remain open to examination for the U.K. Certain tax years remain open to examination under the statute of limitations of the respective countries in which our other foreign subsidiaries are located.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income tax. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration